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Abstract
Background: It is not clear whether bone turnover markers can be used to make inference
regarding changes in bone mineral density (BMD) in untreated healthy elderly men. The present
study was designed to address three specific questions: (i) is there a relationship between bone
turnover markers and femoral neck BMD within an individual; (ii) is there a relationship between
baseline measurements of bone turnover markers and subsequent change in BMD; and (iii) is there
a relationship between changes in bone turnover markers and changes in femoral neck BMD?
Methods: The present study was part of the on-going Dubbo Osteoporosis Epidemiology Study,
which was designed as a prospective investigation. Men who had had at least 3 sequential visits with
serum samples available during follow-up were selected from the study population. Serum C-
terminal telopeptide of type I collagen (sICTP), N-terminal propeptide of type I collagen (sPINP)
and femoral neck BMD were measured by competitive radioimmunoassays. Femoral neck bone
mineral density (BMD) was measured by a densitometer (GE Lunar Corp, Madison, WI). Various
mixed-effects models were used to assess the association between the markers and changes in
BMD.
Results: One hundred and one men aged 70 ± 4.1 years (mean ± SD) met the criteria of selection
for analysis. On average, sPINP decreased by 0.7% per year (p = 0.026), sICTP increased by 1.7%
per year (p = 0.0002), and femoral neck BMD decreased by 0.4% per year (p < 0.01). Within-subject
analysis indicated that changes in BMD were significantly associated with changes in sPINP (p =
0.022), but not with changes in sICTP (p = 0.84). However, neither baseline sPINP (p = 0.50) nor
baseline sICTP (p = 0.63) was associated with subsequent changes in BMD. Moreover, changes in
BMD were not significantly associated with previous changes in sPINP (p = 0.13) or sICTP (p =
0.95).
Conclusion: These results suggest that in elderly men of Caucasian background, changes in sPINP
were inversely related to changes in BMD within an individual. However, neither sPINP nor sICTP
was sufficiently sensitive to predict the rate of change in BMD for a group of individuals or for an
individual.
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Background
That the continuous remodeling process of bone forma-
tion and bone resorption can be measured by biochemi-
cal bone turnover markers is well-established; however,
due to their substantial intra-subject variability, it remains
controversial whether these indices are useful in the clini-
cal setting. Being able to predict the change in bone min-
eral density (BMD) for an individual is of importance, as
it may help to manage the disease progression and poten-
tially provides an opportunity for intervention to reduce
the fracture risk for the individual. A number of studies,
mainly in women, have suggested that the association
between bone turnover markers and change in BMD
ranged from non-significant [1] or weak [2-4] to moderate
association [5].
Bone loss (as measured by BMD) is less pronounced in
men than in women [6,7], and the association between
bone turnover markers and BMD is unclear. Cross-sec-
tional studies in men have demonstrated that PINP, a
bone formation marker, decreases with advancing age,
but was paradoxically negatively correlated with BMD
[8,9]. In a prospective study, again in elderly men, an
increase in either PINP or ICTP was associated with
increased loss of femoral neck BMD [10]. However, most
of these studies were cross-sectional nature, and therefore,
important questions on the within-subject relationships
between bone turnover markers and change in BMD
could not be addressed.
The present study was designed to examine the associa-
tion between baseline measures and change in two bone
markers and BMD in a sample of well-characterized eld-
erly men. Three specific questions were asked: First, is
there a relationship between bone turnover markers and
femoral neck BMD within an individual? Second, is there
a relationship between baseline measurements of bone
turnover markers and change in BMD after controlling for
unmeasured factors? These "unmeasured factors" were
modeled by including a term for year, along with random
factor terms for individual. Third, is there a causal relation-
ship between changes in bone turnover markers and
changes in femoral neck BMD?
Methods
Study subjects
The present study was part of the Dubbo Osteoporosis
Epidemiology Study (DOES) for which the study design
and protocol have been described elsewhere [11]. Briefly,
DOES is a longitudinal, population-based study of risk
factors for fracture and mortality. The study was approved
by the St Vincent's Hospital Ethics Committee. Written
informed consent was obtained from each subject. The
study was initiated in mid-1989 and has been on-going
since. By February 2003, 989 men and 1661 women had
participated in the study.
Because the aim was to assess the association between
changes in markers of bone turnover and changes in
BMD, the present study included only men who have
been longitudinally followed for at least 3 visits with
serum samples available during follow-up period. Men
with bone diseases, fractures, acute or chronic illnesses
(i.e. cardiac failure, renal and liver insufficiency, and can-
cer), hypogonadism, or men on any medication affecting
bone metabolism (i.e., glucocorticoids, calcitonin, anti-
convulsants, and vitamin D or analogues) were excluded
from the study. Ultimately, data from 101 men were
included in the analysis. The median duration of follow-
up was 6 years. All men have been scheduled for periodi-
cal visits, separated by an average of 2 years.
Measurements
After obtaining written informed consent, subjects were
interviewed by a nurse co-ordinator who administered a
structured questionnaire to collect data including age,
anthropometric variables, life-style and clinical. Serum
samples were collected in the non-fasting state and stored
at -80°C until analysis.
A marker of bone formation, serum N-terminal propep-
tide of type I collagen (sPINP) and a marker of bone
resorption, serum C-terminal telopeptide of type I colla-
gen (sICTP) were measured in duplicate by competitive
radioimmunoassays (Orion Diagnostica, Espoo, Finland)
[12,13]. The reproducibility of sPINP was 3.1 to 7.7%,
with a male reference range being 21 to 78 μg/L. The
reproducibility of sICTP was 6.7 to 8.5%, with a male ref-
erence range being 1.4 to 5.2 μg/L. All laboratory analyses
were carried out in batches with all samples from a single
subject run in one assay. The same batch of the respective
assay was used for all measurements.
BMD was measured at the lumbar spine and femoral neck
by dual energy X-ray absorptiometry using a LUNAR DPX
densitometer (GE Lunar Corporation, Madison, WI,
USA). The coefficient of reliability of BMD in our institu-
tion in normal subjects is 0.96, and the coefficient of var-
iation was 1.5% at the proximal femur [14]. Quality
control was performed regularly by using phantom to
ensure the reliability of the densitometer. All BMD meas-
urements were performed by the same operator and the
same DXA instrument by a standardized protocol of
measurement.
The primary dependent (outcome) variable used in this
study was change in femoral neck BMD. This choice was
based on the fact that in elderly men femoral neck BMD
measurement is less likely to be affected by degenerativeBMC Musculoskeletal Disorders 2007, 8:13 http://www.biomedcentral.com/1471-2474/8/13
Page 3 of 11
(page number not for citation purposes)
changes than lumbar spine BMD measurement. Thus, the
use of femoral neck BMD as an outcome variable permit-
ted a more reliable and valid way to examine the true rela-
tionship between PINP and ICTP and bone mineral
density.
Statistical analysis
To take full advantage of the hierarchical structure and
longitudinal nature of the study, a mixed-effects linear
model was considered. Various mixed-effects models con-
taining both fixed and random effects and adjusted for the
within-subject correlation [15] were considered. Model
development was guided by the research questions.
Details of these statistical models are shown in the Appen-
dix. Briefly, the analysis began with the estimation of the
baseline value and rate of change in BMD for each indi-
vidual, assuming a linear function of time. The baseline
value here refers to the intercept of an individual [15]. The
collection of the rates of change across individuals was
assumed to be normally distributed with a mean β and
variance  . To address the first question (i.e., within-
subjects correlation between bone turnover markers and
BMD), a slight modification of the above model was con-
sidered in that association between bone turnover mark-
ers and BMD, the variation of BMD within an individual
was modeled as a linear function of the individual's sPINP
or sICTP over time. To address the second question (i.e.,
association between baseline bone turnover markers and
subsequent changes in BMD), the individual intercepts
and slopes of the outcome-time model were modeled as a
linear function of baseline measurements of PINP and
ICTP. The SAS PROC MIXED procedure [16] was used to
derive estimates of the mixed-effects model parameters.
Finally, to address the causative relationship between
change in bone turnover markers and change in BMD, a
first-order autoregressive model was used. In this model,
the difference in BMD between visit 3 and visit 2 (BMD3-
2) was modeled as a linear function of the difference in
PINP (or ICTP) between visit 2 and visit 1 (PINP2-1 or
ICTP2-1) such that BMD3-2 = α + β (PINP2-1) + γ (ICTP2-1)
+ e, where e is the residual error term, and α, β and γ are
regression coefficients to be estimated from the sample of
101 individuals. The estimates of these parameters were
obtained by the least squares method with PROC REG of
the SAS systems [17].
Results
The 101 men had been followed for a median of 6 years
(range: 4 to 10 years). At baseline (first visit) the men's
average age was 70 years (SD: 4.1 years) (Table 1). All
bone turnover markers and BMD measurements were nor-
mally distributed with no evidence of outliers or skewness
of distribution. Cross-sectionally, there was a weak and
statistically non-significant correlation between baseline
femoral neck BMD and baseline PINP (r = -0.14; p = 0.14)
and ICTP (r = 0.15, p = 0.14) (Figure 1).
Rates of change in BMD, sPINP and sICTP
In longitudinal analyses (Table 2), femoral neck BMD
decreased by 3.5 ± 1.0 mg/cm2 per year (mean ± SE; p <
0.001), while lumbar spine BMD increased by 7 ± 1.3 mg/
cm2 per year (p < 0.001). When expressed in percentage
terms, these changes were equivalent to -0.4% per year for
the femoral neck and +0.6% per year for the lumbar spine.
As indicated by the estimated variance of slopes ( ), the
rates of change in femoral neck BMD varied significantly
among individuals (44 ± 16; p = 0.004); however, the rate
of change in lumbar spine BMD did not differ signifi-
cantly among individuals (p = 0.47). The non-significant
covariance ( ) suggests that the baseline and rate of
change in BMD were not significantly correlated.
The marker of bone formation, sPINP, decreased at the
rate of -0.4 ± 0.18 μg/L or 0.7% per year (p = 0.026),
whereas the resorption marker, sICTP, increased by 0.08 ±
0.02 μg/L or 1.7% per year (p = 0.0002). There was no sta-
tistically significant variation in the rates of change in
sICTP or sPINP among individuals.
When comparing the unconditional linear change model
with the unconditional mean model, 34% of the within-
subject variance in BMD was attributable to time. How-
ever, time explained a modest proportion of within-sub-
ject variance in sPINP (10%) and sICTP (7%).
Relationships between BMD and sPINP or sICTP within 
individuals
Results of the mixed-effects analysis suggests that after
adjusting for the effect of age, each unit increase in sPINP
was associated with a decrease of 9.2 ± 4.4 mg/cm2 (p =
0.022) in femoral neck BMD. However, there was no sig-
nificant association between changes in sICTP and
changes in femoral neck BMD (p = 0.84) (Table 3). Com-
pared with the unconditional linear change model in
Table 2, the inclusion of sPINP or sICTP in the model
accounted for a further 0.5% and 0.1% reduction in the
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Relationships between baseline sPINP or sICTP and 
change in BMD
Further analysis suggested that the rate of change in fem-
oral neck BMD was not significantly correlated to baseline
sPINP (p = 0.28) or sICTP (p = 0.71). Compared with the
model shown in Table 3, the inclusion of baseline sPINP
or sICTP did not significantly reduce the within-subject
variance in BMD (Table 4 and Figure 2).
Causal relationship between change in femoral neck BMD 
and change in sPINP
Changes in sPINP and sICTP between visit 2 and visit 1
were not significant predictors of subsequent change in
femoral neck BMD between visit 3 and visit 2 (Figure 3).
However, the relationship was consistent with results
from the within-subject analysis. For instance, each unit
increase in sPINP between visit 2 and visit 1 was related to
a subsequent decrease in femoral neck BMD of 0.6 ± 0.4
mg/cm2, but the relationship was not statistically signifi-
cant (p = 0.18).
Table 1: Characteristics of study subjects at baseline
Variable Mean (standard deviation) 5th and 95th quantile
Age (yr) 70.4 (4.1) 66, 82
Weight (kg) 80.5 (12.3) 63, 102
Height (cm) 173.7 (6.4) 162, 183
Body mass index (kg/m2) 26.6 (3.4) 22.3, 34.3
sPINP(μg/L) 39.8 (13.1) 22.8, 67.1
sICTP (μg/L) 4.2 (1.1) 2.9, 6.8
Lumbar spine BMD (g/cm2) 1.29 (0.21) 0.98, 1.68
Femoral neck BMD (g/cm2) 0.95 (0.13) 0.73, 1.15
Duration of follow-up (yrs) 5.9 (1.5) 4.0, 8.9
sICTP, serum C-terminal telopeptide of type I collagen; sPINP, serum N-terminal propeptide of type I collagen; BMD bone mineral density.
Relationship between baseline sPINP (left panel) or sICTP (right panel) and femoral neck BMD Figure 1
Relationship between baseline sPINP (left panel) or sICTP (right panel) and femoral neck BMD.BMC Musculoskeletal Disorders 2007, 8:13 http://www.biomedcentral.com/1471-2474/8/13
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Discussion
Bone loss results from an imbalance between the two
processes of bone resorption and bone formation, which
can be measured by bone turnover markers. One of the
suppositions in using bone turnover markers is to make
inference regarding the magnitude of changes in bone
density. In this study of untreated elderly men, a signifi-
cant increase in bone resorption (as measured by sICTP),
decrease in bone formation (as measured by sPINP), and
decrease in femoral neck BMD were observed. Despite
this, neither baseline measurement of, nor the change in,
sPINP or sICTP predicted the subsequent rate of change in
BMD.
It should be noted that the rate of change in BMD and the
rate of change in either serum markers of bone turnover in
this study was modest. However, such modest changes
should not affect the predictive relationship between the
bone turnover markers and BMD, should it exist, as the
variance of rates of change was substantial in both mark-
ers and BMD. Furthermore, the current sample size had a
more than 80% chance to detect a correlation of 0.2 at the
significance level of 5% should the association exist: the
sample size required to detect a correlation of 0.25 at the
significance level of 5% is approximately 62 subjects).
Therefore, the present study's non-significant results are
unlikely to be due to the study's power or the distribution
of bone loss of change in sPINP or sICTP.
In elderly women, a combination of three biochemical
markers accounted for more than 50% of the variance in
bone mineral density [18]. Skeletal turnover rates appear
to be as much as 85% higher in elderly women with low
bone mass, compared with women who have normal
bone density. Furthermore, in a large prospective study of
elderly postmenopausal women in Europe [19], levels of
osteocalcin,  C-telopeptides, and bone-specific alkaline
phosphatase were all significantly greater in older than
younger women. Furthermore, these bone formation
markers were inversely related to femoral bone mineral
density.
However, the situation in men remains largely unclear. In
a relatively small longitudinal study of 24 men, whose
BMD, sPINP and sICTP were measured 3 years apart,
change in BMD was significantly and inversely correlated
with change in sPINP (r = -0.24; p = 0.05) and change in
sICTP (r = -0.24; p = 0.01) [10]. However, it was not clear
Table 2: Rates of change in bone mineral density and bone turnover markers
Symbol Estimated parameters ± standard error (SE) for
Femoral neck BMD Lumbar spine BMD sPINP sICTP
Parameters
Baselinea α 943.0 ± 13** 1288.0 ± 20.3** 40. 1 ± 1.3* 4.3 ± 0.12**
Rate of changeb β -3.5 ± 1.0** 7.4 ± 1.3** -0.4 ± 0.18* 0.08 ± 0.02*
Variance components
Baseline 16650 ± 2453** 38968 ± 5883** 130.8 ± 25* 0.81 ± 0.22**
Rate of change 44 ± 6* 2 ± 30 0.4 ± 0.51 0.01 ± 0.05
Covariance 43 ± 135 876 ± 283** -1.1 ± 2.7 0.07 ± 0.03**
Random error 908 ± 131** 3234 ± 327** 52.6 ± 6.8** 0.84 ± 0.08**
sICTP, serum C-terminal telopeptide of type I collagen; sPINP, serum N-terminal propeptide of type I collagen; BMD bone mineral density.
Units of measurement: abaseline parameters were expressed in mg/cm2 (for bone mineral density) and μg/L (for sPINP and sICTP); brate of 
change: mg/cm2 per year (for bone mineral density) and μg/L per year (for sPINP and sICTP).
Note of interpretation: For femoral neck BMD, the overall average baseline measurement was 943 mg/cm2, and the rate of change was -3.5 mg/
cm2 per year. The standard deviation (SD) of baseline BMD among individuals was   = 129 mg/cm2, and the SD of rates of change among 
individuals was   = 6.6 mg/cm2. More importantly, the variance in BMD within individuals was 908 mg2/cm4. The covariance was not 
statistically significant, which suggests that there was no significant correlation between the baseline measurements and rates of change in BMD.
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from that study whether both factors were independent
predictors of BMD change if they were considered simul-
taneously in the same model, or whether baseline sPINP
and sICTP was predictive of subsequent change in BMD.
These results together with those of the present study
clearly suggest that the contribution of bone turnover
markers to the prediction of change in BMD is minimal.
Indeed, variation in sPINP and sICTP accounts for less
than 1% of the variance of rates of change in BMD within
subjects.
In interpreting the association between bone turnover
markers and BMD, it is important to make distinction
between a between-subject correlation from within-sub-
ject correlation between change in sPINP (or sICTP) and
change in BMD. Previous studies [20,21] examined the
between-subject correlation, whereas the present study
primarily examined the within-subjects association. For
example, it was observed in this study that although the
between-subject correlation between sICTP and femoral
neck BMD was statistically significant (r = 0.15, p = 0.03),
Table 3: Within-subject association between femoral neck BMD and bone turnover markers.
Symbol Estimate ± SE P-value
Analysis marker: sPINP
Estimated parameters
Intercept (baseline) α 944 ± 13 <0.0001
Rate of change β -3.7 ± 1.0 0.0004
sPINP γ -9.2 ± 4.4 0.022
Variance components
Baseline 16428 ± 2425 <0.001
Rate of change 38 ± 16 0.009
Covariance 72 ± 131 0.586
Random error 903 ± 134 <0.001
Analysis marker: sICTP
Estimated parameters
Intercept (baseline) α 943 ± 13 <0.0001
Rate of change β -3.4 ± 1.0 0.0013
sICTP γ -0.7 ± 3.6 0.8425
Variance components
Baseline 16677 ± 2462 <0.0001
Rate of change 44 ± 16 0.0041
Covariance 43 ± 135 0.7526
Random error 907 ± 130 <0.0001
sICTP, serum C-terminal telopeptide of type I collagen; sPINP, serum N-terminal propeptide of type I collagen; BMD bone mineral density.
Note of interpretation: Results in part (a) suggest that the BMD measurement (mg/cm2) for a subject at time t (denoted by BMDt) can be 
represented by the equation: BMDt = 944 – 3.7*Year – 9.2* sPINPt, where "Year" is 0, 1, 2, ..., and sPINPt is the measurement of sPINP at time t for 
the subject. In other words, femoral neck BMD was decreased by -3.7 mg/cm2 per year. Furthermore, each 1 μg/L increase in sPINP was associated 
with a 9.2 mg/cm2 decrease in BMD. The interpretation of variance components is similar to that in Table 2. For example, the SD of baseline BMD 
among individuals was   = 129 mg/cm2, and the SD of rates of change among individuals was   = 6.6 mg/cm2. The within-individuals 
variance in BMD was 907 mg2/cm4, a slight reduction from 908 mg2/cm4 (Table 2), which suggests that including sPINP did not have a substantial 
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the within-subject correlation was not. Thus, while indi-
viduals with higher/lower levels of sICTP may have lower/
higher BMD, the increase in sICTP within an individual
does not necessarily translating into a decrease in BMD.
More importantly, there was no causal relationship
between change in either sICTP or sPINP and change in
BMD, as the preceding change in the markers was not a
significant predictor of subsequent change in BMD.
A number of studies in women have suggested that a base-
line measurement of bone resorption markers such as uri-
nary CTx [19], urinary NTx [19], urinary free dPyr [22]
and sICTP [23] was each associated with fracture risk [5].
Thus, although sICTP was not a significant predictor of
change in BMD it is a predictive of fracture risk, independ-
ent of BMD. Indeed, in this cohort, baseline measurement
of sICTP, but not sPINP, was found to be an independent
predictor of fracture risk, such that a combination of
sICTP and femoral neck BMD yielded a better predictive
value than either measurement [24].
Measurements of bone turnover markers in serum are
generally considered to be more reliable and more accu-
rate than those measured in urine, as the confounding
errors associated with creatinine measurement are largely
eliminated. Nevertheless, the within-subject biological
variation in sPINP and sICTP was around 20% [5], which
in turn can be attributed to factors such as non-uniform
Table 4: Association between baseline PINP, ICTP and change in femoral neck BMD
Symbol Estimate ± SE P-value
Analysis marker: sPINP
Estimated parameters
Intercept (baseline) α 943 ± 13 <0.0001
Rate of change β -3.5 ± 1.0 0.0004
sPINP γ 0.7 ± 1.1 0.4953
Variance components
Baseline 16661 ± 2454 <0.001
Rate of change 44 ± 16 0.004
Covariance 54 ± 131 0.692
Random error 902 ± 130 <0.001
Analysis marker: sICTP
Estimated parameters
Intercept (baseline) α 943 ± 13 <0.0001
Rate of change β -3.6 ± 1.0 0.0008
sICTP γ -0.6 ± 1.3 0.629
Variance components
Baseline 16643 ± 2453 <0.0001
Rate of change 43 ± 16 0.0041
Covariance 56 ± 139 0.6848
Random error 907 ± 131 <0.0001
sICTP, serum C-terminal telopeptide of type I collagen; sPINP, serum N-terminal propeptide of type I collagen; BMD bone mineral density.
Note of interpretation: Results in part (a) suggest that the BMD measurement (mg/cm2) for a subject at time t (denoted by BMDt) can be 
represented by the equation: BMDt = 943 – 3.5*Year – 9.2* sPINP0, where "Year" is 0, 1, 2, ..., and sPINP0 is the measurement of sPINP at baseline 
for the subject. In other words, femoral neck BMD was decreased by -3.5 mg/cm2 per year. There was no significant association between baseline 
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rates of bone turnover, variable rates of metabolism and
clearance, diurnal and seasonal variability, and other fac-
tors affecting pre-analytic variability. This relatively large
variation in bone turnover markers can compromise the
relationship between change in these markers and change
in BMD within an individual.
Inaccuracy and unreliability of measurements, including
within-subject random variability, can affect the delinea-
tion of the association between bone turnover markers
and BMD or fracture risk in some epidemiological studies.
Theoretically, if the coefficients of reliability of BMD and
sPINP are r1 and r2, respectively, then it can be shown that
the maximum squared correlation between the two varia-
bles is r1r2 [25]. In our study, r1 = 0.96 and r2 = 0.91, then
the maximally expected squared correlation between
BMD and sPINP is 0.87. However, in reality the correla-
tion was 0.0196. Given the imprecision, this correlation
could be about 0.0196/0.87 = 0.022. Therefore, it seems
the imprecision of measurement did not account for the
modest association that we observed in this study.
The decrease in sPINP and increase in sICTP observed in
this study are indications of reduced bone formation and
increased bone resorption activities. This is consistent
with the established fact that androgen levels (free or
available testosterone) decrease with advancing age
[26,27]. Reduced testosterone is associated with bone loss
in men [28], probably associated with a reduction in vita-
min D levels leading to calcium malabsorption and
reduced bone formation [29]. Recently, the important
role of estrogen in the regulation of bone metabolism in
men has been recognized [30], because estrogen controls
bone resorption in elderly men [31]. The present study
did not measure estrogen in these men, therefore it was
not possible to examine the relationship between estro-
gen and the bone turnover markers. Although vitamin D
was not measured in these men, in a study of men in the
same cohorts from whom the present study's men were
selected, the prevalence of vitamin D deficiency was
extremely low (less than 1%). Thus, the present study's
result was unlikely to be compromised by vitamin D sta-
tus.
Conclusion
In summary, the present study suggests that in a group of
non-treated elderly men of Caucasian background, the
change in the rate of bone formation, as measured by
sPINP, was associated with the change in BMD within a
subject. However, neither sPINP nor sICTP was suffi-
ciently sensitive to predict the rate of change in BMD for a
group of individuals or for an individual.
Relationship between change in femoral neck BMD and baseline sPINP (left panel) or sICTP (right panel) Figure 2
Relationship between change in femoral neck BMD and baseline sPINP (left panel) or sICTP (right panel).BMC Musculoskeletal Disorders 2007, 8:13 http://www.biomedcentral.com/1471-2474/8/13
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Appendix: mixed-effects models
In what follows i denotes study subjects (i = 1, 2, 3, ...,
101), and t denotes visits (t = 1, 2, 3). The measurement
of each outcome variable, BMD, PINP, and ICTP, taken at
the tth visit for the ith subject is denoted by BMDit, PINPit,
and ICTPit, respectively. The duration of follow-up for the
tth visit, calculated from the initial visit, is denoted by Tit,
where Ti1 = 0. The change in each outcome variable for
each subject was first modeled as a linear function of time
(also called the unconditional linear growth model) as
follows:
BMDit = αi + βiTit + eit   (1)
where α i denotes the BMD measurement at the initial visit
(baseline value) and β i denotes the rate of change in BMD
per year for the ith subject, and eit denotes the within-sub-
ject random variation. The baseline BMD of the ith subject
was then modeled as a function of population mean, α,
and a deviation from the population mean, ri: αi = α + ri.
Similarly, the rate of change for the ith subject was
assumed to be equal to an overall mean rate of change, β,
and a deviation from the mean associated with the ith
individual, si: βi = β + si. Therefore, the BMD values of the
ith subject in (1) can now be written as:
BMDit = α + βTit + ri + siTit + eit   (2)
PINPit  and  ICTPit  were also modeled similarly. It is
assumed that eit are independently normally distributed
with mean 0 and variance  . The distributions of ri and
si are assumed to be normal with mean 0, variances of 
and  , respectively, and a covariance of  .
For interpretation, α represents the population mean of
an outcome measure (i.e., BMD, PINP or ICTP), β repre-
sents the average linear annual rate of change in the out-
come measure;   represents the within-subject variance
or the pooled deviation of each subject's measure around
his "true" average;   is the between-subject variance of
the measure;   is the between-subject variance of the
linear rates of change in the measure; and   represents
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change. The estimates of α, β, , ,  ,  and   are
shown in Table 2.
To address the first aim (e.g., is there an association
between PINP or ICTP and BMD within individuals),
model (1) was extended to accommodate the effect of
PINP or ICTP:
BMDit = αi + βiTit + γ(PINPit) + eit
or BMDit = αi + βiTit + γ(ICTPit) + eit   (3)
where αi = α + ri, βi = β + si as above, and γ i are assumed to
be a fixed effect. Note that unlike α i and β i, the coefficient
associated with PINP or ICTP is assumed to be a constant
across subjects. Therefore, the BMD values of the ith sub-
ject can now be written as: BMDit = α + βTit + γPINPit + ri +
siTit + eit or BMDit = α + βTit + γICTPit + ri + siTit + eit. The esti-
mates of α, β, γ,  ,  ,  , and   are shown in
Table 3.
To address the second aim (e.g., whether baseline PINP or
ICTP predicts the change in BMD), the coefficients of time
effects in model (1) was modeled as a function of baseline
PINP or ICTP as follows: βi = β + ηPINPi0 + si or βi = β +
ηICTPi0 + si Therefore the model becomes:
BMDit = α + (β + ηPINPi0 + si)Tit + ri + eit
BMDit = α + (β + ηICTPi0 + si)Tit + ri + eit   (4)
The estimates of α,  β,  η,  ,  ,  , and   are
shown in Table 4.
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